Photo from Unsplash

Originally Posted On: https://sloanestreetsurgery.co.uk/mens-health/understanding-the-stockholm-3-test-for-prostate-cancer-a-qa-guide/

The Stockholm 3 test is an advanced blood test that helps detect prostate cancer more accurately than the traditional PSA (Prostate Specific Antigen) test. It combines the results of several biomarkers, genetic markers, and clinical information, offering a clearer understanding of a man’s risk of developing aggressive prostate cancer.

While the PSA test only measures the level of PSA in the blood, which can be elevated due to various reasons (such as benign prostate conditions), the Stockholm 3 test evaluates multiple biomarkers and genetic factors. This makes it more specific, reducing the number of false positives and providing a better indication of whether aggressive prostate cancer is present.

No, the Stockholm 3 test does not completely replace the PSA test. It is often used after an initial PSA screening, especially when PSA levels are elevated or unclear. The Stockholm 3 test complements the PSA test by offering more detailed risk assessment and helping doctors make more informed decisions about further testing, such as MRI scans or biopsies.

Yes, the Stockholm 3 test can, in some cases, reduce the need for an MRI. If the test results show a low risk of aggressive prostate cancer, it may help avoid unnecessary imaging. However, if the test indicates a higher risk, an MRI may still be recommended to get additional information before considering a biopsy. The decision depends on the individual case and your doctor’s assessment.

The Stockholm 3 test is mainly recommended for men aged 50 to 70 who are at risk for prostate cancer or have elevated PSA levels but no clear diagnosis. It is particularly useful for men with inconclusive PSA results or those wanting more clarity before deciding whether to have a biopsy.

Research shows that the Stockholm 3 test is more accurate than the PSA test alone. It can reduce unnecessary biopsies by about 30% while still identifying aggressive cancers that require treatment. This helps avoid the stress and potential complications of unnecessary procedures, while still catching cancer early in men who need treatment.

Not necessarily. The test is a useful tool in deciding whether a biopsy is needed. If the results indicate a high risk of aggressive prostate cancer, a biopsy may still be necessary. However, for men with a lower risk based on the Stockholm 3 test, it may help avoid an unnecessary biopsy.

The Stockholm 3 test is a simple blood test. A blood sample is taken and sent to a laboratory, where the biomarkers and genetic markers are analysed. Your doctor will review the results with you and explain your risk level for prostate cancer based on the test.

The test involves only a standard blood draw, so the risks are minimal. You may experience slight bruising or discomfort at the site of the blood draw, but serious side effects are very rare.

If you are interested in the Stockholm 3 test, talk to your doctor. They can help determine if the test is appropriate for you based on your PSA levels, risk factors, and medical history.

The Stockholm 3 test provides a more comprehensive risk assessment for prostate cancer compared to the PSA test alone. It can reduce the likelihood of unnecessary procedures and help detect aggressive cancers that require early treatment. It’s a valuable tool for men who want more clarity about their prostate cancer risk.

The new spit test, part of the ongoing BARCODE1 study, is designed to assess a man’s genetic risk of developing prostate cancer using a simple saliva sample. This test analyses a polygenic risk score (PRS), which looks at variations in many genes associated with prostate cancer. The aim of the BARCODE1 study is to determine how well this genetic information can predict prostate cancer risk and guide early detection and personalised screening strategies.

The spit test provides a non-invasive way to gather genetic information, offering an alternative or additional method to PSA and other blood tests. By identifying men at higher genetic risk, it could help target screening and interventions more effectively, potentially reducing the need for unnecessary biopsies and identifying aggressive cancers earlier.

While this genetic testing is still in the research phase, it represents a promising future for personalised prostate cancer screening, complementing tools like the PSA test and the Stockholm 3 test.

The Stockholm 3 test is an important advancement in prostate cancer screening. It improves accuracy, reduces unnecessary biopsies and MRI scans, and helps identify aggressive cancers early. Book a consultation with your doctor to discuss if this test is right for you.

To book an appointment online click here or call us on 0207 245 3999.